VICTORIA, BC and SAN DIEGO, CA, March 29 /PRNewswire-FirstCall/ - Stressgen Biotechnologies Corporation ("Stressgen" or the "Corporation") announced today that the TSX has issued a bulletin confirming the listing on the TSX of Stressgen's common shares and warrants in substitution for the presently listed common shares and warrants of GVIC Publications Ltd. (formerly "Stressgen Biotechnologies Corporation") ("GVIC Publications").
The Corporation's common shares and warrants will commence trading on the TSX at the opening on Thursday, March 30, 2006 under the symbol "SSB", and the presently listed common shares and warrants of GVIC Publications will be delisted at that time. A copy of the TSX bulletin may be found on the TSX website at www.tsx.com.
The substitutional listing follows the March 23, 2006 completion of the Corporation's previously announced corporate reorganization involving Stressgen, GVIC Publications and 0747036 B.C. Ltd. ("Investor"), an affiliate of Glacier Ventures International Corp., an information communications company listed on the TSX.
Following completion of the reorganization, Stressgen has established a new SEDAR profile. Historical information concerning the Corporation's management, business and operations can be found on the SEDAR website at www.sedar.com under GVIC Publications' SEDAR profile.
About Stressgen Biotechnologies Corporation
Stressgen is developing innovative therapeutics for the treatment of viral infections, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol SSB. For more information about Stressgen, please visit the Company's website at www.stressgen.com.
Director, Investor Relations
6055 Lusk Boulevard
San Diego, CA USA 92121
Stressgen Biotechnologies Corp.
CONTACT: Donna Slade, Director, Investor Relations, 6055 Lusk Boulevard,San Diego, CA, USA 92121, Tel: (858) 202-4900, Dir: (858) 202-4945, Fax:(858) 450-6849, email@example.com